The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
ACADEMIA
Ivermectin Fails in Investigator-Led COVID Trial Too
Kitasato University Hospital said on September 30 that the antiparasitic agent ivermectin could not yield a statistically significant difference against placebo in the primary endpoint in an investigator-initiated trial for the treatment of COVID-19.The news comes just days after Kowa…
To read the full story
Related Article
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- MHLW to Fund Development of Kowa’s Ivermectin for COVID-19
March 7, 2022
- Ivermectin Shows Antiviral Effects against Omicron: Kowa
February 1, 2022
- Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
ACADEMIA
- Diabetes Society Flags DKA Risk for AstraZeneca’s Truqap after Report of Death
April 21, 2025
- iPSC-Derived Cells Effective in Parkinson’s, Approval Could Come in FY2025
April 21, 2025
- Researchers Succeed in Transplanting iPS Cell Sheets for Type 1 Diabetes Patient
April 15, 2025
- NCCH Launches Pilot for Online Screening of Clinical Trial Participants
March 6, 2025
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…